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Identity 
Other names: GSF, IDX-1, IPF1, IUF1, MODY4, 
PDX-1, STF-1 




PDX-1 gene is located at human chromosome 13q12.1, 
mouse chromosome 5qG3 and rat chromosome 12, 
respectively. 
PDX-1 gene consists of two exons spanning a region of 
about 6 kb. In the promoter region of PDX-1, there a
three highly conserved regions, termed "Area I-II-III" 
which are located between -2800 and -1600 base pairs
(bp), and a forth distal enhancer element, termed "Area 
IV" which is located between -6500 and -6045 bp. 
These enhancer elements harbor binding sites for 
multiple transcription factors and transcriptional 
regulators such as HNF-1alpha, HNF-3beta, HNF-6, 
Foxa1, Foxa2, Pax6, MafA and PDX-1 itself. Areas I 
and II impart endocrine expression, while Area III 
confers beta-cell specificity. Area IV is capable of  
independently directing pancreatic beta-cell-specific 
reporter gene expression and potentiating the proximal 
enhancer activity. 
Transcription 
PDX-1 mRNA has an open reading frame of 849 bp. 
Protein 
Description 
Human PDX-1 is a protein of 283 amino acids with a 
calculated molecular weight of 30.64 kDa. However, 
endogenous PDX-1 is usually detected as a protein with 
molecular mass of 46 kDa, likely due to 
posttranslational modifications such as phosphorylation 
and sumoylation. The N-terminus of PDX-1 contains a 
transactivation domain. The middle region contains a 
homeodomain, which is essential for DNA binding and 
protein-protein interactions. Within the homeodomain, 
there is an antennapedia-like protein transduction 
domain (PTD) which allows PDX-1 to permeate into 
cells and a nuclear localization signal (NLS) motif, 
RRMKWKK(197-203aa), which is sufficient for the 
nuclear import of PDX-1. There is a conserved motif in 
the C-terminus of PDX-1 that mediates the 
 
Figure 1. Schematic representation of functional domains and phosphorylation sites of PDX-1. The numbers indicate the positions 
of phosphorylation sites and functional domains on the polypeptide chain of human PDX-1. NLS: Nuclear localization signal; PTD: 
Protein transduction domain; S: Serine; T: Threonine. 
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PDX-1-PCIF1 interaction resulting in the inhibition of 
PDX-1 transcriptional activity. Several C-terminal 
residues such as Gly 212, Glu 224 and Pro 239 are 
essential for full transactivation of PDX-1 as evidenced 
by the association of their missense mutations with 
diabetes (Fig. 2). Several potential phosphorylation 
sites within PDX-1 have been identified, such as Thr 11 
by DNA-PK, Ser 61 and 66 by GSK3beta, Thr 152 by 
PASK, Thr 231 and Ser 232 by CK2 and Ser 268 by 
AKT-GSK and HIPK2. 
Expression 
PDX-1 is expressed as early as embryonic day 8.5 
(E8.5) in the dorsal and ventral endoderm regions that
give rise to pancreatic buds, as well as in the comm n 
bile duct, distal stomach, Brunner's glands, and 
duodenal epithelium. During pancreas development, 
PDX-1 is expressed in all pancreatic precursor cells. 
PDX-1 expression becomes restricted to beta cells and 
a small subpopulation of delta and PP cells in adult. 
Low levels of PDX-1 are also detected in the nuclei of 
acinar cells. PDX-1 is also expressed in the gastric 
antrum and duodenum in adult. 
The compartmentalization of PDX-1 is lost under 
pathological conditions. Aberrant overexpression of 
PDX-1 is observed in a number of human cancers such
as pancreatic, gastric, colon, breast, prostate, colorectal, 
kidney cancer and paediatric solid pseudopapillary 
tumors. Up-regulated PDX-1 expression is also 
observed in premalignant metaplastic ductal epithelium 
during transforming growth factor (TGF)-alpha-
induced pancreatic ductal metaplasia and neoplasia. 
PDX-1 expression is subject to regulation by glucose, 
glucagon-like peptide 1 (GLP-1), palmitic acid, 
peroxisome proliferator-activated receptor-alpha 
(PPARalpha) and PPARgamma, epidermal growth 
factor (EGF) and high fat diet. 
Localisation 
PDX-1 is localized in the Nucleus of the cells. In solid 
pseudopapillary tumors (SPT), however, PDX-1 only 
exists in the cytoplasm, but not in the nucleus. 
Function 
Pancreatic and duodenal homeobox-1 (PDX-1) is a 
homeodomain-containing transcription factor essential 
for pancreatic development, beta-cell differentiation 
and the maintenance of mature beta cell function 
through regulating the expression of key endocrine 
beta-cell-specific genes such as insulin, glucokinase, 
islet amyloid polypeptide and the glucose transporter 
type 2. PDX-1 also regulates the expression of elastase 
I in pancreatic ductal and acinar cells. PDX-1 is 
functionally involved in mitochondrial signal 
generation in the moment-to-moment control of insulin 
release by regulating mitochondrial transcription factor 
A (TFAM). 
Homology 
Human PDX-1 shares a 90% amino acid homology 
with hamster, 88% with rat, 87% with mouse and 68% 
with Xenopus. Zebrafish PDX-1 shares a 95% amino 




Pro63fsdelC: a frameshift mutation resulting from a 
single nucleotide deletion within codon 63 in exon 1 of 
the coding sequence of PDX-1. The point deletion 
causes a frame shift resulting in the translation of 59 
novel codons before termination and the production of 
a prematurely terminated truncated protein of 16 kDa. 
InsCCG243: an in-frame proline insertion mutation at 
codon 243 of PDX-1. 
Missense mutations: C18R, P33T, Q59L, D76N, 
E178G, R197H, G212R, E224K and P239Q. These 
missense mutants show either a decreased binding 
activity to the insulin gene promoter (C18R, P33T, 
D76N and R197H) or a reduced transactivity (C18R, 
P33T, Q59L, D76N, E178G, R197H, G212R, E224K 
and P239Q) compared to wild-type PDX-1. 
 
Figure 2. Diabetes-associated genetic mutations of PDX-1. MODY4/3: maturity-onset diabetes of young 43; P: proline; C: cysteine; E: 
glutamic acid; K: lysine; R: arginine; Q: glutamine; L: leucine; D: aspartic acid; N: asparagine; G: glycine; H: histidine. 










Elevated expression of PDX-1 is found in a number of 
human cancers, including pancreatic, breast, prostate 
cancer, colorectal cancer, colon cancer, kidney, gastric, 
paediatric solid pseudopapillary tumors (SPT) and 
intestinal-type ovarian mucinous neoplasm (OMN). 
Elevated expression level of PDX-1 in pancreatic 
cancer is significantly correlated with lymph node 
metastasis, TNM grading, pathological grading and 
tumor cell proliferation. PDX-1 expression in 
pancreatic cancer is an independent survival factor 
since the patients with positive PDX-1 have a 
significantly worse prognosis than those patients with 
negative PDX-1. In colorectal cancer, PDX-1 is highly 
expressed in hepatic metastasis of colorectal cancer, 
while lower expression of PDX-1 is found in primary 
colorectal tumor. Metastatic colorectal adenocarcinoma 
in the ovarian is also positive for PDX-1. PDX-1 
expression also correlates with histological type and 
depth of invasion of gastric carcinomas. 
Diabetes 
Prognosis 
Maturity-onset diabetes of young 4 (MODY4) is a form 
of early-onset type-II diabetes mellitus in which 
expression of diabetes occurs later than that observed 
for MODY1, MODY2 and MODY3. Pro63fsdelC of 
PDX-1 contributes to the development of MODY4 
when the mutation is heterozygous. InsCCG243, PDX-
1 P33T and PDX-1 E224K mutations also contribute to 
the development of MODY4. Two missense mutations 
(D76N and P239Q) in PDX-1 are found in MODY3 
families. Five missense mutations (C18R, Q59L, 
D76N, E178G and R197H) in PDX-1 are found in 
patients with Non-MODY type 2 diabetes. 
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